α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study
Objective To comprehensively analyze the 5‐year outcomes of tamsulosin treatment for patients with benign prostatic hyperplasia. Methods Tamsulosin (0.2 mg/day) was given to 112 patients who had International Prostate Symptom Scores ≥8. They were prospectively followed for 5 years with periodic eval...
Gespeichert in:
| Veröffentlicht in: | International journal of urology 2013-04, Vol.20 (4), p.421-428 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 428 |
|---|---|
| container_issue | 4 |
| container_start_page | 421 |
| container_title | International journal of urology |
| container_volume | 20 |
| creator | Masumori, Naoya Tsukamoto, Taiji Horita, Hiroki Sunaoshi, Ken-ichi Tanaka, Yoshinori Takeyama, Koh Sato, Eiji Miyao, Noriomi |
| description | Objective
To comprehensively analyze the 5‐year outcomes of tamsulosin treatment for patients with benign prostatic hyperplasia.
Methods
Tamsulosin (0.2 mg/day) was given to 112 patients who had International Prostate Symptom Scores ≥8. They were prospectively followed for 5 years with periodic evaluation. If tamsulosin had to be discontinued, the reason was determined. Treatment failure was considered in the case of disease progression (postvoid residual urine volume ≥200 mL, acute urinary retention, febrile urinary tract infection or hydronephrosis as a result of bladder outlet obstruction), conversion to other α1‐blockers or need for surgery. An intention‐to‐treat analysis was carried out.
Results
A total of 34 patients (30.4%) continued the same medication for the overall study period, whereas 78 patients (69.6%) discontinued the medication. International Prostate Symptom Scores, Benign Prostatic Hyperplasia Problem Index and Quality of Life Index were significantly improved over the 5‐year period. Treatment failure was observed in 21 patients (18.8%). Baseline prostate volume and postvoid residual urine volume were independent factors to predicting treatment failure. A total of 21 patients (18.8%) discontinued tamsulosin because of an improvement of symptoms. They were younger and had lower prostate‐specific antigen levels than the remaining 91 patients. Their symptoms were stable even 1 year after termination of therapy.
Conclusions
Long‐term efficacy of tamsulosin was observed, although only a small portion of patients continued the treatment. α1‐blocker monotherapy might be not appropriate for achieving a good long‐term outcome in patients with a large prostate volume and a large amount of postvoid residual urine volume. Persistent improvement of symptoms, even after termination of tamsulosin, was observed in young patients with low prostate‐specific antigen levels. |
| doi_str_mv | 10.1111/j.1442-2042.2012.03165.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1324385014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1324385014</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3755-cd8231e0046d24ccfed4c39817ff7734486f781030c5d9857918a71f5a86378a3</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhS0EaofSV0BesknwXxIHiQWqYFqoyoaKpeVxbqinzg-2Qycvwnv0RfpMOJ0y63rjK93zXV-fgxCmJKfpvN_mVAiWMSJYzghlOeG0LPLdC7Q6NF6iFalpnUlasWP0OoQtIZQzKo_QMWO1rLmQK_T34Z5mGzeYW_A46i5Mbgi2xzpg29totcPRg44d9BG3g8ejjjbVAd_ZeIM30NtfPR79EGJqGHwzj-BHp4PVH3CRzaA9HqZohg6w7rWbgw14aLF-ZEYw0f4B3E0uwWlsWiLEqZnfoFetdgFOn-4TdP3l84-z8-zy-_ri7NNlZnhVFJlpJOMUCBFlw4QxLTTC8Dp9uW2rigshy7aSlHBiiqaWRVVTqSvaFlqWvJKan6B3-7lpm98ThKg6Gww4p3sYpqCSYYLLglCRpHIvNWnx4KFVo7ed9rOiRC2pqK1azFeL-WpJRT2monYJffv0yrTpoDmA_2NIgo97wZ11MD97sLr4er1Uic_2vA0Rdgde-1tVVskp9fNqnaqy_rZmQp3zf4N1rWU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1324385014</pqid></control><display><type>article</type><title>α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Masumori, Naoya ; Tsukamoto, Taiji ; Horita, Hiroki ; Sunaoshi, Ken-ichi ; Tanaka, Yoshinori ; Takeyama, Koh ; Sato, Eiji ; Miyao, Noriomi</creator><creatorcontrib>Masumori, Naoya ; Tsukamoto, Taiji ; Horita, Hiroki ; Sunaoshi, Ken-ichi ; Tanaka, Yoshinori ; Takeyama, Koh ; Sato, Eiji ; Miyao, Noriomi</creatorcontrib><description>Objective
To comprehensively analyze the 5‐year outcomes of tamsulosin treatment for patients with benign prostatic hyperplasia.
Methods
Tamsulosin (0.2 mg/day) was given to 112 patients who had International Prostate Symptom Scores ≥8. They were prospectively followed for 5 years with periodic evaluation. If tamsulosin had to be discontinued, the reason was determined. Treatment failure was considered in the case of disease progression (postvoid residual urine volume ≥200 mL, acute urinary retention, febrile urinary tract infection or hydronephrosis as a result of bladder outlet obstruction), conversion to other α1‐blockers or need for surgery. An intention‐to‐treat analysis was carried out.
Results
A total of 34 patients (30.4%) continued the same medication for the overall study period, whereas 78 patients (69.6%) discontinued the medication. International Prostate Symptom Scores, Benign Prostatic Hyperplasia Problem Index and Quality of Life Index were significantly improved over the 5‐year period. Treatment failure was observed in 21 patients (18.8%). Baseline prostate volume and postvoid residual urine volume were independent factors to predicting treatment failure. A total of 21 patients (18.8%) discontinued tamsulosin because of an improvement of symptoms. They were younger and had lower prostate‐specific antigen levels than the remaining 91 patients. Their symptoms were stable even 1 year after termination of therapy.
Conclusions
Long‐term efficacy of tamsulosin was observed, although only a small portion of patients continued the treatment. α1‐blocker monotherapy might be not appropriate for achieving a good long‐term outcome in patients with a large prostate volume and a large amount of postvoid residual urine volume. Persistent improvement of symptoms, even after termination of tamsulosin, was observed in young patients with low prostate‐specific antigen levels.</description><identifier>ISSN: 0919-8172</identifier><identifier>EISSN: 1442-2042</identifier><identifier>DOI: 10.1111/j.1442-2042.2012.03165.x</identifier><identifier>PMID: 22989348</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Adrenergic alpha-1 Receptor Antagonists - administration & dosage ; Adrenergic alpha-1 Receptor Antagonists - adverse effects ; Aged ; alpha 1-blocker ; benign prostatic hyperplasia ; Disease Progression ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; long-term outcome ; Male ; Middle Aged ; Patient Dropouts ; postvoid residual urine volume ; Predictive Value of Tests ; Proportional Hazards Models ; Prospective Studies ; prostate volume ; Prostatic Hyperplasia - drug therapy ; Prostatic Hyperplasia - pathology ; Prostatic Hyperplasia - surgery ; Sulfonamides - administration & dosage ; Sulfonamides - adverse effects ; Treatment Outcome ; Urinary Retention - drug therapy ; Urinary Retention - pathology ; Urinary Retention - surgery ; Urination Disorders - drug therapy ; Urination Disorders - pathology ; Urination Disorders - surgery</subject><ispartof>International journal of urology, 2013-04, Vol.20 (4), p.421-428</ispartof><rights>2012 The Japanese Urological Association</rights><rights>2012 The Japanese Urological Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3755-cd8231e0046d24ccfed4c39817ff7734486f781030c5d9857918a71f5a86378a3</citedby><cites>FETCH-LOGICAL-c3755-cd8231e0046d24ccfed4c39817ff7734486f781030c5d9857918a71f5a86378a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1442-2042.2012.03165.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1442-2042.2012.03165.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22989348$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Masumori, Naoya</creatorcontrib><creatorcontrib>Tsukamoto, Taiji</creatorcontrib><creatorcontrib>Horita, Hiroki</creatorcontrib><creatorcontrib>Sunaoshi, Ken-ichi</creatorcontrib><creatorcontrib>Tanaka, Yoshinori</creatorcontrib><creatorcontrib>Takeyama, Koh</creatorcontrib><creatorcontrib>Sato, Eiji</creatorcontrib><creatorcontrib>Miyao, Noriomi</creatorcontrib><title>α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study</title><title>International journal of urology</title><addtitle>Int J Urol</addtitle><description>Objective
To comprehensively analyze the 5‐year outcomes of tamsulosin treatment for patients with benign prostatic hyperplasia.
Methods
Tamsulosin (0.2 mg/day) was given to 112 patients who had International Prostate Symptom Scores ≥8. They were prospectively followed for 5 years with periodic evaluation. If tamsulosin had to be discontinued, the reason was determined. Treatment failure was considered in the case of disease progression (postvoid residual urine volume ≥200 mL, acute urinary retention, febrile urinary tract infection or hydronephrosis as a result of bladder outlet obstruction), conversion to other α1‐blockers or need for surgery. An intention‐to‐treat analysis was carried out.
Results
A total of 34 patients (30.4%) continued the same medication for the overall study period, whereas 78 patients (69.6%) discontinued the medication. International Prostate Symptom Scores, Benign Prostatic Hyperplasia Problem Index and Quality of Life Index were significantly improved over the 5‐year period. Treatment failure was observed in 21 patients (18.8%). Baseline prostate volume and postvoid residual urine volume were independent factors to predicting treatment failure. A total of 21 patients (18.8%) discontinued tamsulosin because of an improvement of symptoms. They were younger and had lower prostate‐specific antigen levels than the remaining 91 patients. Their symptoms were stable even 1 year after termination of therapy.
Conclusions
Long‐term efficacy of tamsulosin was observed, although only a small portion of patients continued the treatment. α1‐blocker monotherapy might be not appropriate for achieving a good long‐term outcome in patients with a large prostate volume and a large amount of postvoid residual urine volume. Persistent improvement of symptoms, even after termination of tamsulosin, was observed in young patients with low prostate‐specific antigen levels.</description><subject>Adrenergic alpha-1 Receptor Antagonists - administration & dosage</subject><subject>Adrenergic alpha-1 Receptor Antagonists - adverse effects</subject><subject>Aged</subject><subject>alpha 1-blocker</subject><subject>benign prostatic hyperplasia</subject><subject>Disease Progression</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>long-term outcome</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient Dropouts</subject><subject>postvoid residual urine volume</subject><subject>Predictive Value of Tests</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>prostate volume</subject><subject>Prostatic Hyperplasia - drug therapy</subject><subject>Prostatic Hyperplasia - pathology</subject><subject>Prostatic Hyperplasia - surgery</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - adverse effects</subject><subject>Treatment Outcome</subject><subject>Urinary Retention - drug therapy</subject><subject>Urinary Retention - pathology</subject><subject>Urinary Retention - surgery</subject><subject>Urination Disorders - drug therapy</subject><subject>Urination Disorders - pathology</subject><subject>Urination Disorders - surgery</subject><issn>0919-8172</issn><issn>1442-2042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAUhS0EaofSV0BesknwXxIHiQWqYFqoyoaKpeVxbqinzg-2Qycvwnv0RfpMOJ0y63rjK93zXV-fgxCmJKfpvN_mVAiWMSJYzghlOeG0LPLdC7Q6NF6iFalpnUlasWP0OoQtIZQzKo_QMWO1rLmQK_T34Z5mGzeYW_A46i5Mbgi2xzpg29totcPRg44d9BG3g8ejjjbVAd_ZeIM30NtfPR79EGJqGHwzj-BHp4PVH3CRzaA9HqZohg6w7rWbgw14aLF-ZEYw0f4B3E0uwWlsWiLEqZnfoFetdgFOn-4TdP3l84-z8-zy-_ri7NNlZnhVFJlpJOMUCBFlw4QxLTTC8Dp9uW2rigshy7aSlHBiiqaWRVVTqSvaFlqWvJKan6B3-7lpm98ThKg6Gww4p3sYpqCSYYLLglCRpHIvNWnx4KFVo7ed9rOiRC2pqK1azFeL-WpJRT2monYJffv0yrTpoDmA_2NIgo97wZ11MD97sLr4er1Uic_2vA0Rdgde-1tVVskp9fNqnaqy_rZmQp3zf4N1rWU</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>Masumori, Naoya</creator><creator>Tsukamoto, Taiji</creator><creator>Horita, Hiroki</creator><creator>Sunaoshi, Ken-ichi</creator><creator>Tanaka, Yoshinori</creator><creator>Takeyama, Koh</creator><creator>Sato, Eiji</creator><creator>Miyao, Noriomi</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201304</creationdate><title>α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study</title><author>Masumori, Naoya ; Tsukamoto, Taiji ; Horita, Hiroki ; Sunaoshi, Ken-ichi ; Tanaka, Yoshinori ; Takeyama, Koh ; Sato, Eiji ; Miyao, Noriomi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3755-cd8231e0046d24ccfed4c39817ff7734486f781030c5d9857918a71f5a86378a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adrenergic alpha-1 Receptor Antagonists - administration & dosage</topic><topic>Adrenergic alpha-1 Receptor Antagonists - adverse effects</topic><topic>Aged</topic><topic>alpha 1-blocker</topic><topic>benign prostatic hyperplasia</topic><topic>Disease Progression</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>long-term outcome</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient Dropouts</topic><topic>postvoid residual urine volume</topic><topic>Predictive Value of Tests</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>prostate volume</topic><topic>Prostatic Hyperplasia - drug therapy</topic><topic>Prostatic Hyperplasia - pathology</topic><topic>Prostatic Hyperplasia - surgery</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - adverse effects</topic><topic>Treatment Outcome</topic><topic>Urinary Retention - drug therapy</topic><topic>Urinary Retention - pathology</topic><topic>Urinary Retention - surgery</topic><topic>Urination Disorders - drug therapy</topic><topic>Urination Disorders - pathology</topic><topic>Urination Disorders - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Masumori, Naoya</creatorcontrib><creatorcontrib>Tsukamoto, Taiji</creatorcontrib><creatorcontrib>Horita, Hiroki</creatorcontrib><creatorcontrib>Sunaoshi, Ken-ichi</creatorcontrib><creatorcontrib>Tanaka, Yoshinori</creatorcontrib><creatorcontrib>Takeyama, Koh</creatorcontrib><creatorcontrib>Sato, Eiji</creatorcontrib><creatorcontrib>Miyao, Noriomi</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Masumori, Naoya</au><au>Tsukamoto, Taiji</au><au>Horita, Hiroki</au><au>Sunaoshi, Ken-ichi</au><au>Tanaka, Yoshinori</au><au>Takeyama, Koh</au><au>Sato, Eiji</au><au>Miyao, Noriomi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study</atitle><jtitle>International journal of urology</jtitle><addtitle>Int J Urol</addtitle><date>2013-04</date><risdate>2013</risdate><volume>20</volume><issue>4</issue><spage>421</spage><epage>428</epage><pages>421-428</pages><issn>0919-8172</issn><eissn>1442-2042</eissn><abstract>Objective
To comprehensively analyze the 5‐year outcomes of tamsulosin treatment for patients with benign prostatic hyperplasia.
Methods
Tamsulosin (0.2 mg/day) was given to 112 patients who had International Prostate Symptom Scores ≥8. They were prospectively followed for 5 years with periodic evaluation. If tamsulosin had to be discontinued, the reason was determined. Treatment failure was considered in the case of disease progression (postvoid residual urine volume ≥200 mL, acute urinary retention, febrile urinary tract infection or hydronephrosis as a result of bladder outlet obstruction), conversion to other α1‐blockers or need for surgery. An intention‐to‐treat analysis was carried out.
Results
A total of 34 patients (30.4%) continued the same medication for the overall study period, whereas 78 patients (69.6%) discontinued the medication. International Prostate Symptom Scores, Benign Prostatic Hyperplasia Problem Index and Quality of Life Index were significantly improved over the 5‐year period. Treatment failure was observed in 21 patients (18.8%). Baseline prostate volume and postvoid residual urine volume were independent factors to predicting treatment failure. A total of 21 patients (18.8%) discontinued tamsulosin because of an improvement of symptoms. They were younger and had lower prostate‐specific antigen levels than the remaining 91 patients. Their symptoms were stable even 1 year after termination of therapy.
Conclusions
Long‐term efficacy of tamsulosin was observed, although only a small portion of patients continued the treatment. α1‐blocker monotherapy might be not appropriate for achieving a good long‐term outcome in patients with a large prostate volume and a large amount of postvoid residual urine volume. Persistent improvement of symptoms, even after termination of tamsulosin, was observed in young patients with low prostate‐specific antigen levels.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>22989348</pmid><doi>10.1111/j.1442-2042.2012.03165.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0919-8172 |
| ispartof | International journal of urology, 2013-04, Vol.20 (4), p.421-428 |
| issn | 0919-8172 1442-2042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1324385014 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adrenergic alpha-1 Receptor Antagonists - administration & dosage Adrenergic alpha-1 Receptor Antagonists - adverse effects Aged alpha 1-blocker benign prostatic hyperplasia Disease Progression Follow-Up Studies Humans Kaplan-Meier Estimate long-term outcome Male Middle Aged Patient Dropouts postvoid residual urine volume Predictive Value of Tests Proportional Hazards Models Prospective Studies prostate volume Prostatic Hyperplasia - drug therapy Prostatic Hyperplasia - pathology Prostatic Hyperplasia - surgery Sulfonamides - administration & dosage Sulfonamides - adverse effects Treatment Outcome Urinary Retention - drug therapy Urinary Retention - pathology Urinary Retention - surgery Urination Disorders - drug therapy Urination Disorders - pathology Urination Disorders - surgery |
| title | α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T21%3A48%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%CE%B11-blocker%20tamsulosin%20as%20initial%20treatment%20for%20patients%20with%20benign%20prostatic%20hyperplasia:%205-year%20outcome%20analysis%20of%20a%20prospective%20multicenter%20study&rft.jtitle=International%20journal%20of%20urology&rft.au=Masumori,%20Naoya&rft.date=2013-04&rft.volume=20&rft.issue=4&rft.spage=421&rft.epage=428&rft.pages=421-428&rft.issn=0919-8172&rft.eissn=1442-2042&rft_id=info:doi/10.1111/j.1442-2042.2012.03165.x&rft_dat=%3Cproquest_cross%3E1324385014%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1324385014&rft_id=info:pmid/22989348&rfr_iscdi=true |